摘要
目的探讨双嘧达莫联合丙种球蛋白治疗小儿川崎病的效果及对基质金属蛋白酶水平的影响。方法选取2019年1月至2022年1月收治的86例川崎病患儿为研究对象,以随机数字表法将其分为对照组和观察组,各43例。两组均予以阿司匹林等药物对症治疗,对照组在此基础上采用丙种球蛋白治疗,观察组采用双嘧达莫联合丙种球蛋白治疗。比较两组的治疗效果。结果观察组的治疗总有效率高于对照组(P<0.05)。治疗后,观察组的纤维蛋白原(Fbg)水平低于对照组(P<0.05)。治疗后,观察组的内皮抑素(ES)、血管内皮生长因子(VEGF)水平均低于对照组(P<0.05)。治疗后,观察组的基质金属蛋白酶-2(MMP-2)、基质金属蛋白酶-9(MMP-9)水平均低于对照组(P<0.05)。结论双嘧达莫联合丙种球蛋白治疗小儿川崎病的效果显著,可促进患儿凝血功能、血管内皮功能改善,也能调节基质金属蛋白酶水平。
Objective To investigate the effect of dipyridamole combined with gamma globulin in the treatment of children with Kawasaki disease and its influence on matrix metalloproteinase level.Methods A total of 86 children with Kawasaki disease admitted from January 2019 to January 2022 were selected as the study objects and divided into control group and observation group by random number table method,with 43 cases in each group.Both groups were given symptomatic treatment with aspirin and other drugs,the control group was treated with gamma globulin on this basis,and the observation group was treated with dipyridamole combined with gamma globulin.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05).After treatment,the fibrinogen(Fbg)level in the observation group was lower than that in the control group(P<0.05).After treatment,the levels of endostain(ES)and vascular endothelial growth factor(VEGF)in the observation group were lower than those in the control group(P<0.05).After treatment,the levels of matrix metalloproteinases-2(MMP-2)and matrix metalloproteinases-9(MMP-9)in the observation group were lower than those in the control group(P<0.05).Conclusion Dipyridamole combined with gamma globulin has a remarkable effect in the treatment of children with Kawasaki disease,which can promote the improvement of blood coagulation function and vascular endothelial function of children,and also regulate the level of matrix metalloproteinase.
作者
马晓鹏
郝婷婷
惠鑫
刘甜
李兴珍
严晓华
MA Xiaopeng;HAO Tingting;HUI Xin;LIU Tian;LI Xingzhen;YAN Xiaohua(Yan'an University Affiliated Hospital,Yan'an 716000;Shaanxi Provincial People's Hospital,Xi'an 710068,China)
出处
《临床医学研究与实践》
2023年第31期22-25,共4页
Clinical Research and Practice
基金
陕西省重点研发计划项目(No.2019SF-112)。
关键词
双嘧达莫
丙种球蛋白
川崎病
基质金属蛋白酶
dipyridamole
gamma globulin
Kawasaki disease
matrix metalloproteinase